ConvaTec Group stock (GB00BD3VFW73): medical products specialist in focus after recent trading update

ConvaTec Group, the UK-based medical products company focused on wound, ostomy and continence care, has remained in the spotlight after its recent trading and outlook updates for 2025, which followed the publication of its full-year 2024 results and guidance earlier this year, according to company and exchange disclosures from March and April 2025 from ConvaTec and the London Stock Exchange.

As of: 05/13/2026

By the editorial team – specialized in equity coverage.

ConvaTec Group: core business model

ConvaTec Group focuses on medical technologies used primarily in chronic care settings, including products for patients with long-term wound, ostomy and continence needs. The company designs and manufactures dressings, ostomy bags and related accessories that support quality of life for patients after surgery or with chronic conditions, according to corporate materials published on its website on 03/14/2025 and product descriptions updated in 2024 from ConvaTec Group as of 03/14/2025.

Its business model combines manufacturing of specialized devices with a sales and distribution network that reaches hospitals, clinics, homecare providers and pharmacies across Europe, North America and other regions. ConvaTec’s portfolio includes advanced wound care dressings for conditions such as pressure ulcers and diabetic foot ulcers, ostomy care appliances including one-piece and two-piece systems, as well as continence and critical care products, according to segment descriptions in the company’s annual report for 2024 published on 03/07/2025 by ConvaTec Group as of 03/07/2025.

In addition to its core chronic care portfolio, ConvaTec also operates an infusion care business that supplies sets and components used with insulin pumps and other therapies. Many of these products are sold under long-term supply contracts with device makers, which can provide recurring revenue streams and visibility over future volumes, according to the same 2024 annual report and associated investor presentation dated 03/07/2025 from ConvaTec Group.

Main revenue and product drivers for ConvaTec Group

ConvaTec’s revenue is generated across four primary segments: Advanced Wound Care, Ostomy Care, Continence & Critical Care and Infusion Care. According to the company’s full-year 2024 results released on 03/07/2025, Advanced Wound Care and Ostomy Care together accounted for a substantial share of group sales, reflecting the underlying demand for products used in managing chronic wounds and stomas, as reported by ConvaTec Group as of 03/07/2025.

In the Advanced Wound Care segment, the company offers foam dressings, hydrofiber dressings and other advanced materials that are designed to support faster healing and infection control. Growth in this area tends to be linked to demographic trends such as aging populations, rising prevalence of diabetes and increased focus on preventing complications from chronic wounds. Hospital procurement practices, reimbursement levels and clinical guidelines in key markets such as the United States and Western Europe also influence purchasing patterns, according to market commentary from 04/15/2025 by Fact.MR as of 04/15/2025.

Ostomy Care represents another major revenue driver, with a product range that includes ostomy pouches, baseplates and accessories for patients who have undergone surgery involving colostomy, ileostomy or urostomy. Demand in this segment is relatively stable and closely tied to the number of surgeries performed, as well as long-term patient adherence to specific systems. Brand loyalty and product reliability are key, as many patients use the same manufacturer’s system for years, and ConvaTec competes with companies such as Coloplast and Hollister in this space, according to market share discussions included in the 2024 annual report issued on 03/07/2025 by ConvaTec Group.

The Continence & Critical Care segment covers solutions for urinary and fecal management in both acute and chronic settings. Products include catheters, urine collection systems and fecal management tools that help manage incontinence and protect skin integrity. While these products often face pricing pressure from healthcare systems, they can be supported by evidence that shows benefits such as reduced infection rates or shorter hospital stays, as outlined in product and clinical reference materials reviewed on 03/20/2025 from ConvaTec Group as of 03/20/2025.

Infusion Care, the fourth segment, supplies infusion sets and related components primarily for subcutaneous insulin delivery but also for other therapies. This business is frequently influenced by contract wins or losses with leading diabetes device companies. Volumes can scale with global adoption of insulin pumps and continuous glucose monitoring systems, particularly in the US and Europe, where access to advanced diabetes care technologies has been expanding, as mentioned in the company’s 2024 results announcement and 2025 trading update released on 04/09/2025 by ConvaTec Group.

Industry trends and competitive position

ConvaTec operates in a competitive medical devices landscape that includes specialized chronic care companies and diversified healthcare groups. In ostomy and wound care, competitors such as Coloplast, Hollister and Smith & Nephew also provide advanced solutions, and market share can shift based on product innovation, service support and pricing. The global stoma and ostomy care market is projected to grow over the coming decade, driven by aging populations and rising chronic disease burdens, according to a stoma care market outlook published on 04/15/2025 by Fact.MR as of 04/15/2025.

Regulation and reimbursement frameworks play a crucial role in this industry. In Europe, reimbursement tends to be coordinated through national health systems, while in the United States, Medicare, Medicaid and private insurers influence how products are covered and at what price. Companies like ConvaTec must navigate product approval pathways, quality standards and post-market surveillance requirements, which can raise entry barriers but also increase operating complexity, according to sector commentary in 2024 medical device regulatory summaries reviewed on 11/10/2024 by S&P Global Market Intelligence.

Innovation is a key differentiator, with firms investing in new materials, skin-friendly adhesives, antimicrobial technologies and digital tools that support patient monitoring or supply management. ConvaTec has highlighted innovation and portfolio expansion as strategic priorities, alongside improving efficiency and profitability, in its 2024 annual report and 2025 outlook statements released on 03/07/2025, which detail spending on research and development and initiatives to streamline operations, according to ConvaTec Group’s investor communications as of 03/07/2025.

Why ConvaTec Group matters for US investors

Although ConvaTec is headquartered and listed in the United Kingdom, its products are widely used in the United States, particularly in wound management, ostomy care and infusion therapy. The company sells into US hospitals, outpatient clinics and homecare channels, meaning that revenue exposure to the American healthcare system is significant, according to geographic breakdowns in the 2024 annual report published on 03/07/2025 by ConvaTec Group as of 03/07/2025.

For US investors looking beyond domestic listings, ConvaTec’s London-traded shares provide exposure to structural themes such as aging populations, chronic disease management and adoption of advanced wound and ostomy technologies across developed markets. Some US-based investors may also access the company through over-the-counter instruments that reference the London-listed stock, depending on broker offerings, as indicated by cross-listing information from international trading platforms compiled on 01/22/2025 by Nasdaq and the London Stock Exchange.

Currency is an additional consideration for US-based shareholders. ConvaTec reports in US dollars but its shares trade in British pounds on the London Stock Exchange, so total returns for US investors can be influenced by movements in the GBP/USD exchange rate. This adds a layer of foreign exchange exposure on top of the underlying business performance, as discussed in risk disclosures in the company’s 2024 annual report released on 03/07/2025 by ConvaTec Group.

Conclusion

ConvaTec Group combines a focus on chronic care specialties with a global footprint across wound, ostomy, continence and infusion products. Its recent reporting cycle and trading updates for 2025 have kept attention on how the company converts demographic and healthcare demand trends into sustainable revenue and margin performance. For US-focused investors, the stock offers exposure to medical devices used widely in American hospitals and homecare environments, while also introducing considerations such as UK equity market dynamics and currency movements. As with any healthcare-focused investment, outcomes will depend on factors including product innovation, competitive positioning, regulatory developments and the broader financial health of healthcare systems in its core markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.